[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509720":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":32,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":7,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":7,"maxAge":7,"enrollmentInfo":43,"targetDuration":46,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Jinling Hospital, China","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Le Qe, M.D.","CONTACT","15720625951","septsoul@hotmail.com",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China","RECRUITING","Nanjing","Jiangsu","210000","China","CN",{"type":24,"coordinates":25},"Point",[26,27],118.77778,32.06167,{"lat":27,"lon":26},[30],{"name":31,"role":11,"phone":12,"phoneExt":7,"email":13},"Le Qu, M.D.",{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Le Qu","Associate chief urologist","100509720","renal-cancer-monitoring-based-on-ctdna-methylomics-a-prospective-cohort-study-memory-study-100509720",false,"NCT05917106","Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)","Inclusion Criteria:\n\n* Newly diagnosed renal cell carcinoma\n* Without any treatment\n* Agree and accept radical surgical treatment\n* Signed written informed consent\n* ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1\n* Follow up protocol and related procedures\n\nExclusion Criteria:\n\n* Had other cancers\n* Had received any antitumor therapy before\n* Known or suspected active autoimmune disease\n* Informed consent is not possible due to medical or psychiatric problems\n* Have clinical symptoms or diseases of the heart that are not well controlled\n* Patients judged by the investigators to be unsuitable for inclusion in this study","ALL",{"count":44,"type":45},450,"ESTIMATED","5 Years","OBSERVATIONAL","To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.",[50,51,52,53,54],"Carcinoma","Renal Cell Carcinoma","RCC","Kidney Neoplasms","Kidney Cancer","2025-12-04",{"date":57,"type":58},"2025-12-11","ACTUAL",{"date":60,"type":58},"2022-12-26",{"date":62,"type":45},"2030-06",{"name":5,"class":6},1]